Reactivation of desensitized formyl peptide receptors by platelet activating factor: a novel receptor cross talk mechanism regulating neutrophil superoxide anion production.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Neutrophils/*metabolism ; Platelet Activating Factor/*pharmacology ; Receptors, Formyl Peptide/*metabolism ; Superoxides/*metabolism; Actins/metabolism ; Azepines/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Calcium/metabolism ; Cells, Cultured ; Cyclosporine/pharmacology ; Cytochalasin B/pharmacology ; Cytoskeleton/drug effects ; Cytoskeleton/metabolism ; Gelsolin/pharmacology ; Humans ; Marine Toxins ; NADPH Oxidases/metabolism ; Neutrophils/drug effects ; Neutrophils/enzymology ; Oligopeptides ; Oxazoles/pharmacology ; Peptide Fragments/pharmacology ; Receptors, Formyl Peptide/agonists ; Receptors, Formyl Peptide/antagonists & inhibitors ; Thiazolidines/pharmacology ; Triazoles/pharmacology
    • Abstract:
      Neutrophils express different chemoattractant receptors of importance for guiding the cells from the blood stream to sites of inflammation. These receptors communicate with one another, a cross talk manifested as hierarchical, heterologous receptor desensitization. We describe a new receptor cross talk mechanism, by which desensitized formyl peptide receptors (FPRdes) can be reactivated. FPR desensitization is induced through binding of specific FPR agonists and is reached after a short period of active signaling. The mechanism that transfers the receptor to a non-signaling desensitized state is not known, and a signaling pathway has so far not been described, that transfers FPRdes back to an active signaling state. The reactivation signal was generated by PAF stimulation of its receptor (PAFR) and the cross talk was uni-directional. LatrunculinA, an inhibitor of actin polymerization, induced a similar reactivation of FPRdes as PAF while the phosphatase inhibitor CalyculinA inhibited reactivation, suggesting a role for the actin cytoskeleton in receptor desensitization and reactivation. The activated PAFR could, however, reactivate FPRdes also when the cytoskeleton was disrupted prior to activation. The receptor cross talk model presented prophesies that the contact on the inner leaflet of the plasma membrane that blocks signaling between the G-protein and the FPR is not a point of no return; the receptor cross-talk from the PAFRs to the FPRdes initiates an actin-independent signaling pathway that turns desensitized receptors back to a signaling state. This represents a novel mechanism for amplification of neutrophil production of reactive oxygen species.
    • References:
      Trends Neurosci. 2005 Jul;28(7):371-8. (PMID: 15979501)
      J Immunol. 1998 Mar 1;160(5):2463-8. (PMID: 9498791)
      Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S123-31. (PMID: 21195301)
      Nat Rev Drug Discov. 2010 May;9(5):373-86. (PMID: 20431569)
      Br J Pharmacol. 2012 Mar;165(6):1717-1736. (PMID: 21699508)
      Free Radic Biol Med. 2012 Jul 1;53(1):72-80. (PMID: 22583699)
      Eur J Pharmacol. 2008 May 13;585(2-3):278-91. (PMID: 18410914)
      J Biol Chem. 1996 Nov 8;271(45):28717-24. (PMID: 8910508)
      Scand J Immunol. 1991 Dec;34(6):697-712. (PMID: 1749920)
      Eur J Immunol. 2007 Apr;37(4):1087-96. (PMID: 17330823)
      Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6682-6. (PMID: 8692878)
      J Biol Chem. 2000 Sep 8;275(36):28120-7. (PMID: 10859320)
      J Immunol Methods. 2010 Jan 31;352(1-2):45-53. (PMID: 19891970)
      Curr Biol. 2008 Jun 3;18(11):R485-94. (PMID: 18522824)
      J Biol Chem. 1993 Nov 15;268(32):24247-54. (PMID: 8226971)
      Biochim Biophys Acta. 1994 Oct 20;1224(1):43-50. (PMID: 7948041)
      Eur J Haematol. 1993 Nov;51(5):288-93. (PMID: 8282090)
      Mol Pharmacol. 2011 Nov;80(5):760-8. (PMID: 21836019)
      Methods Mol Biol. 2006;332:3-49. (PMID: 16878684)
      Trends Pharmacol Sci. 2011 Sep;32(9):521-33. (PMID: 21680031)
      Biochem J. 1992 Sep 15;286 ( Pt 3):687-92. (PMID: 1417726)
      Trends Pharmacol Sci. 2011 Jan;32(1):35-42. (PMID: 21075459)
      J Biol Chem. 2003 Aug 15;278(33):30578-86. (PMID: 12773548)
      Cell Signal. 2011 Apr;23(4):621-9. (PMID: 20946952)
      J Leukoc Biol. 2006 Dec;80(6):1214-21. (PMID: 16943386)
      Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11564-8. (PMID: 1763071)
      J Immunol. 1987 Nov 15;139(10):3447-55. (PMID: 2824606)
      Free Radic Biol Med. 1996;20(6):785-92. (PMID: 8728025)
      J Biol Chem. 1986 Oct 15;261(29):13662-9. (PMID: 3020040)
      Cell Signal. 2007 Sep;19(9):1939-48. (PMID: 17594911)
      Cell Signal. 2003 Jun;15(6):549-57. (PMID: 12681442)
      Bioessays. 1994 Mar;16(3):193-8. (PMID: 8166673)
      J Recept Signal Transduct Res. 2010 Oct;30(5):313-21. (PMID: 20858023)
      Methods Mol Biol. 2007;412:349-63. (PMID: 18453123)
      Pharmacol Rev. 2009 Jun;61(2):119-61. (PMID: 19498085)
      J Leukoc Biol. 2006 Feb;79(2):247-56. (PMID: 16365159)
      Scand J Immunol. 2011 Sep;74(3):227-234. (PMID: 21535079)
      J Immunol. 2006 May 1;176(9):5418-25. (PMID: 16622009)
      Prog Lipid Res. 2005 Mar-May;44(2-3):154-83. (PMID: 15893379)
      J Leukoc Biol. 1997 Jun;61(6):753-8. (PMID: 9201267)
      Immunology. 2004 Jun;112(2):201-10. (PMID: 15147563)
      Science. 2010 Oct 15;330(6002):362-6. (PMID: 20947763)
      Immunol Today. 2000 Jun;21(6):260-4. (PMID: 10939787)
      Cell Mol Life Sci. 2009 Sep;66(18):2953-73. (PMID: 19597700)
      J Immunol. 1994 Oct 1;153(7):3267-75. (PMID: 8089498)
      Mol Pharmacol. 2009 Jan;75(1):227-34. (PMID: 18931035)
      Pharmacol Rev. 2011 Mar;63(1):59-126. (PMID: 21228259)
      J Biol Chem. 1999 Mar 5;274(10):6027-30. (PMID: 10037679)
      J Immunol. 1993 Apr 15;150(8 Pt 1):3534-45. (PMID: 8468487)
      J Cell Biol. 2002 Oct 14;159(1):91-102. (PMID: 12370241)
      Traffic. 2006 Oct;7(10):1420-31. (PMID: 16899088)
    • Accession Number:
      0 (Actins)
      0 (Azepines)
      0 (Bridged Bicyclo Compounds, Heterocyclic)
      0 (Gelsolin)
      0 (Marine Toxins)
      0 (Oligopeptides)
      0 (Oxazoles)
      0 (Peptide Fragments)
      0 (Platelet Activating Factor)
      0 (Receptors, Formyl Peptide)
      0 (Thiazolidines)
      0 (Triazoles)
      0 (gelsolin (160-169))
      105219-56-5 (WEB 2086)
      11062-77-4 (Superoxides)
      3CHI920QS7 (Cytochalasin B)
      7D07U14TK3 (calyculin A)
      83HN0GTJ6D (Cyclosporine)
      EC 1.6.3.- (NADPH Oxidases)
      FUO6O3NDNH (cyclosporin H)
      SRQ9WWM084 (latrunculin A)
      SY7Q814VUP (Calcium)
    • Publication Date:
      Date Created: 20130405 Date Completed: 20130930 Latest Revision: 20211021
    • Publication Date:
      20240829
    • Accession Number:
      PMC3610682
    • Accession Number:
      10.1371/journal.pone.0060169
    • Accession Number:
      23555913